Latest Daunorubicin Stories
Company expects Induction Response Rate data in Second Quarter of 2015 EWING, N.J., Dec. 1, 2014 /PRNewswire/-- Celator Pharmaceuticals, Inc.
EWING, N.J., Nov. 24, 2014 /PRNewswire/ -- Celator Pharmaceuticals, Inc.
Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising.
Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).
New research published in the March 15 issue of the New England Journal of Medicine (embargoed 5 pm ET March 14) identifies gene mutations associated with improved overall survival with higher doses of chemotherapy for patients with acute myeloid leukemia (AML).
Will a drug used to treat childhood acute lymphoblastic leukemia and other pediatric cancers cause heart problems later in life?
- A transitional zone between two communities containing the characteristic species of each.